Rani Therapeutics Holdings, Inc. (RANI) Balance Sheet

NASDAQ: RANIAssets, liabilities, debt and equity over 7 years.

RANI balance sheet, 2025

December 31, 2025 · U.S. dollars

$58.6M assets = $17.1M liabilities + $41.5M equity

What it owns$58.6MCash & ST investments: $49.7M (84.8%)Cash & ST investments$49.7M · 85%Receivables: $2.0M (3.5%)Other current: $1.6M (2.7%)PP&E: $5.1M (8.6%)PP&E $5.1MOther non-current: $246,000 (0.4%)=How it is financed$58.6MCurrent liabilities: $12.7M (21.6%)Current liabilities$12.7M · 22%Other LT liabilities: $4.4M (7.6%)Other LT liabilities $4.4MShareholders’ equity: $41.5M (70.8%)Shareholders’ equity$41.5M · 71%

Both columns are drawn to the same scale: what RANI owns equals what it owes plus shareholders’ equity. Hover a block for its value.

RANI financial health

Current ratio4.21
Comfortable · current assets cover current liabilities 4.21×
Debt / equity0.13
Low leverage · $0.13 of debt for each $1 of equity
Equity / assets56.3%
Equity-funded · of assets funded by shareholders
Cash / debt1,151.2%
Cash covers debt · cash & short-term investments vs total debt
Goodwill & intangibles0.0%
Mostly tangible · of total assets

Descriptive bands, not a rating. Fiscal 2025.

RANI balance sheet trends, 2019–2025

Rani Therapeutics Holdings, Inc. balance sheet trends
MetricTrendThenLatestChange
Total assets$23.0M2019$58.6M2025+16.9%/yr
Total liabilities$119.7M2019$17.1M2025−27.7%/yr
Shareholders’ equity−$96.6M2019$33.0M2025—
Cash & short-term investments$16.5M2019$49.7M2025+20.1%/yr
Total debt$115.5M2019$4.3M2025−42.2%/yr
Net cash (debt)−$99.0M2019$45.4M2025+$144.4M
Working capital$13.4M2019$40.7M2025+$27.2M
Book value per share$1.552022$0.502025−31.4%/yr
Current ratio4.8420194.212025−0.64
Debt / equity0.8220220.132025−0.69
Shares outstanding23.8M202266.1M2025+40.6%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

RANI assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

RANI liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

RANI debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

RANI balance sheet

Rani Therapeutics Holdings, Inc. annual balance sheet
2025202420232022202120202019
Assets
Cash & short-term investments$49.7M$27.6M$48.5M$98.5M$117.5M$73.1M$16.5M
Cash & equivalents$18.6M$3.8M$5.9M$27.0M$117.5M$73.1M$16.5M
Short-term investments$31.1M$23.9M$42.7M$71.5M$0——
Receivables$2.0M$428,000$200,000$0$0$1.7M$250,000
Inventory$0$0$0$0$0$0$1
Other current assets$1.6M$1.7M$2.1M$2.4M$2.1M$167,000$157,999
Total current assets$53.3M$29.7M$50.8M$100.9M$119.6M$74.9M$16.9M
Property, plant & equipment (net)$5.1M$6.6M$6.8M$7.1M$4.6M$4.5M$4.5M
Goodwill & intangible assets$0$0$0$0$0$0$0
Long-term investments$0$0$0$0$0$0$0
Other non-current assets$246,000$246,000$246,000$0$0$0$1.6M
Total assets$58.6M$36.6M$57.9M$108.0M$124.2M$79.4M$23.0M
Liabilities
Accounts payable$309,000$1.4M$648,000$1.5M$1.1M$537,000$198,000
Short-term debt$1.6M$16.5M$5.6M$1.0M—$1.4M—
Deferred revenue$6.8M−$1.5M$1.2M——$2.7M$179,000
Total current liabilities$12.7M$19.9M$8.0M$4.8M$2.6M$5.3M$3.5M
Long-term debt$0$9.6M$24.5M$29.1M$0$2.4M$0
Lease obligations$4.3M$5.1M$718,000$1.1M$0——
Other long-term liabilities$4.4M$3.6M$0$59,000$1$185.0M$116.2M
Total liabilities$17.1M$33.1M$32.5M$34.0M$2.6M$192.8M$119.7M
Shareholders' equity
Common stock & paid-in capital$11,000$5,000$5,000$5,000$5,000$664,000$664,000
Retained earnings (deficit)−$132.6M−$102.9M−$72.9M−$38.9M−$8.3M−$114.0M−$97.3M
Accumulated other comprehensive income$1,000$5,000−$12,000−$73,000$0−$849,034−$780,160
Minority interest$8.5M$1.5M$12.6M$37.1M———
Total shareholders' equity$33.0M$2.0M$12.9M$36.9M$47.4M−$113.3M−$96.6M
Key figures
Total debt$4.3M$29.7M$30.1M$30.2M—$3.8M$115.5M
Net cash (debt)$45.4M−$2.1M$18.4M$68.3M—$69.3M−$99.0M
Working capital$40.7M$9.9M$42.9M$96.1M$117.0M$69.6M$13.4M
Tangible book value$33.0M$2.0M$12.9M$36.9M$47.4M−$113.3M−$96.6M
Book value per share$0.50$0.07$0.50$1.55———
Shares outstanding66.1M28.5M25.5M23.8M———
Current ratio4.211.506.3620.9645.3014.124.84
Quick ratio4.081.416.1020.4544.4914.094.80
Debt / equity0.1314.912.340.82———
Equity / assets56.3%5.4%22.2%34.1%38.2%−142.7%−419.8%

Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 26, 2026); data from EODHD.

RANI financial position

At the end of fiscal 2025 (December 31, 2025), Rani Therapeutics had total assets of $58.6 million (up 60.0% from a year earlier), total liabilities of $17.1 million and shareholders' equity of $33.0 million. It held $49.7 million in cash and short-term investments against $4.3 million of debt, a net cash position of $45.4 million. Its current ratio was 4.21. In the latest quarter (ended June 30, 2026) total assets were $60.8 million and equity $39.2 million.

Related: RANI income statement, RANI cash flow statement, RANI key metrics. See the RANI stock overview for the latest quote and news.

RANI balance sheet FAQ

What are Rani Therapeutics's total assets?

Rani Therapeutics reported total assets of $58.6 million at the end of fiscal 2025 (December 31, 2025), compared with $36.6 million a year earlier.

How much debt does Rani Therapeutics have?

Rani Therapeutics had $4.3 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.13.

How much cash does Rani Therapeutics have?

Rani Therapeutics held $49.7 million in cash and short-term investments at the end of fiscal 2025; with $4.3 million of debt that is net cash of $45.4 million.

What is Rani Therapeutics's book value?

Rani Therapeutics's shareholders' equity (book value) was $33.0 million at the end of fiscal 2025, or $0.50 per share.

What is Rani Therapeutics's current ratio?

Rani Therapeutics had current assets of $53.3 million and current liabilities of $12.7 million, a current ratio of 4.21 (it can cover its short-term obligations).

Biotechnology: balance sheet